Clinical Trial Update: Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection [Phase 2]

View source ↗

Summary

Phase 2 study evaluating VIR-2218 with or without pegylated interferon alfa-2a for chronic hepatitis B has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Pegylated Interferon Alpha-2a (pegylated interferon alfa-2a)
• VIR-2218

Snippet

Sponsor: Vir Biotechnology, Inc. | Conditions: Chronic Hepatitis B | Phase 2 | Status: COMPLETED | Results posted: 2026-04-16